Skip to main content

SER-287 (SERES-201 study)

The SERES-201 ECO-RESET study is a Phase 2 clinical study evaluating the safety and efficacy of SER-287 versus placebo, in adults with active mild-to-moderate Ulcerative Colitis (UC). This Phase 2 study is based on the positive findings in our Phase 1b study which demonstrated clinical improvement and robust engraftment of SER-287 bacteria. The 201 study is intended to assess the efficacy, safety and microbiome alterations associated with SER-287 when taken by adult patients with UC. The full name of the clinical study is: “A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER‑287 in Adults with Active Mild-to-Moderate Ulcerative Colitis.”

Seres reported positive results of its Phase 1b study of SER-287 in patients with UC. Future development in other forms of IBD are under consideration.

About Ulcerative Colitis

Ulcerative Colitis is a chronic inflammatory condition of the colon, leading to episodes of bloody diarrhea and urgency. The disease mostly affects young and middle-aged individuals. The cause of Ulcerative Colitis is largely unknown. While genetic factors contribute to disease risk, an abnormal relationship between the immune system and intestinal bacteria may also play a role in triggering the disease.

In several previously reported studies, some UC patients with mild-to-moderate disease administered bacteria through fecal microbiota transplant from a healthy donor experienced improvements in their UC symptoms, suggesting that changes in the bacteria may contribute to this clinical response.

SERES-101 Clinical Trial
Learn more about our Phase 1b Trial >

Enrollment is now complete. Please check back.

SERES Therapeutics Pipeline
Learn more about Seres Therapeutics Pipeline >

SER-287 is revolutionizing ulcerative colitis treatment

Join our clinical trial


Ulcerative Colitis

Learn more about Ulcerative Colitis, a form of Inflammatory Bowel Disease


Back to top